⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21585069 | 0.80 | — | — | |
| SCHEMBL13064290 | 0.75 | — | — | |
| SCHEMBL24035061 | 0.72 | — | — | |
| SCHEMBL14533774 | 0.72 | — | — | |
| SCHEMBL15579924 | 0.72 | ALDH1A1 (0.30) | — | |
| SCHEMBL20848140 | 0.72 | — | — | |
| SCHEMBL23714610 | 0.71 | — | — | |
| SCHEMBL24584635 | 0.70 | — | — | |
| SCHEMBL13772846 | 0.70 | — | — | |
| SCHEMBL18708856 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023115327-A1 | PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION | 中国药科大学 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115150-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| WO-2022118016-A2 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-06-09 | — | — | WO | disclosed |
| EP-3383875-B1 | 3-PYRIMIDINYL PYRROLO [2,3-B] PYRIDINE AS ANTICANCER AGENTS AND THE PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2022-02-09 | — | — | EP | disclosed |
| EP-3825314-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | Medshine Discovery Inc. (CN) | 2021-05-26 | — | — | EP | disclosed |
| EP-3545956-B1 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H- PYRROLO[2,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2020-12-16 | — | — | EP | disclosed |
| WO-2020223728-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| EP-3719017-A2 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | Betta Pharmaceuticals Co., Ltd. (CN) | 2020-10-07 | — | — | EP | disclosed |
| WO-2020043658-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-03-05 | — | — | WO | disclosed |
| EP-2931722-B1 | SUBSTITUTED 1H-PYRROLO [2,3-B]PYRIDINE AND 1H-PYRAZOLO [3, 4-B]PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2020015744-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | 南京明德新药研发有限公司 | 2020-01-23 | — | — | WO | disclosed |
| EP-2986300-B1 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H-PYRROLO [2-,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2019-06-26 | — | — | EP | disclosed |